Literature DB >> 2388102

Combined treatment with cyclosporin A and cortisone acetate minimizes the adverse bone effects of either agent alone.

C Movsowitz1, M Schlosberg, S Epstein, F Ismail, M Fallon, S Thomas.   

Abstract

Although cyclosporin A (CsA) and cortisone acetate (CRT) adversely affect bone, their combined effect on bone is unknown. Sprague Dawley rats were therefore administered either vehicle or CsA (7.5 mg/kg/day) by gavage and saline or CRT (2 mg/100 mg/day) by s.c. injection for 28 days. Group A received vehicle plus saline, group B CsA plus saline, group C vehicle plus CRT, and group D CsA/CRT. Serial bloods were sampled over a 28-day period for ionized calcium (Ca), PTH, 1,25 dihydroxyvitamin D (1,25(OH)2D), and bone gla protein (BGP osteocalcin) and tibia were examined on day 28 for histomorphometry. Results were compared with group A. Ca and PTH levels in groups B, C, and D were similar to those in group A during the study period. Group B had lower body weights, elevated levels of BGP, and an increase in 1,25(OH)2D. Group C developed weight loss and a decrease in BGP and 1,25(OH)2D. Group D had weight loss, BGP levels between those of group A and group C, and 1,25(OH)2D values similar to group A. Bone histomorphometry revealed high turnover osteopenia in group B and hyperostosis in group C with a decrease in bone formation and osteoclastlike cells. Combination therapy returned these to control values. In conclusion, the adverse effects of either CsA or CRT on bone in rats are minimized by combined therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2388102     DOI: 10.1002/jor.1100080503

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  7 in total

1.  Correction of metabolic acidosis with potassium citrate in renal transplant patients and its effect on bone quality.

Authors:  Astrid Starke; Alf Corsenca; Thomas Kohler; Johannes Knubben; Marius Kraenzlin; Daniel Uebelhart; Rudolf P Wüthrich; Brigitte von Rechenberg; Ralph Müller; Patrice M Ambühl
Journal:  Clin J Am Soc Nephrol       Date:  2012-07-05       Impact factor: 8.237

2.  Cyclosporin A: friend or foe?

Authors:  S Epstein
Journal:  Calcif Tissue Int       Date:  1991-10       Impact factor: 4.333

Review 3.  Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials.

Authors:  J Wang; M Yao; J-h Xu; B Shu; Y-j Wang; X-j Cui
Journal:  Osteoporos Int       Date:  2016-01-05       Impact factor: 4.507

4.  Lack of change of cancellous bone volume with short-term use of the new immunosuppressant rapamycin in rats.

Authors:  I Joffe; I Katz; S Sehgal; F Bex; Y Kharode; J Tamasi; S Epstein
Journal:  Calcif Tissue Int       Date:  1993-07       Impact factor: 4.333

Review 5.  Drug-induced disorders of bone metabolism. Incidence, management and avoidance.

Authors:  G Jones; P N Sambrook
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

6.  Parathyroid function in cardiac transplant patients: evaluation during physical exercise.

Authors:  G Brandenberger; B Schnedecker; K Spiegel; B Mettauer; B Geny; J Sacrez; E Lampert; J Lonsdorfer
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1995

7.  Cyclophilin A (CypA) Plays Dual Roles in Regulation of Bone Anabolism and Resorption.

Authors:  Mian Guo; Aaron W James; Jin Hee Kwak; Jia Shen; Kazunari K Yokoyama; Kang Ting; Chia B Soo; Robert H Chiu
Journal:  Sci Rep       Date:  2016-03-02       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.